Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - AccuredShares IssuedShares OutstandingShares Outstanding
Ratios

Zentalis Pharmaceuticals (ZNTL) Accumulated Depreciation & Amortization (2021 - 2026)

Zentalis Pharmaceuticals has reported Accumulated Depreciation & Amortization over the past 6 years, most recently at $151000.0 for Q1 2026.

  • For Q1 2026, Accumulated Depreciation & Amortization fell 42.37% year-over-year to $151000.0; the TTM value through Mar 2026 reached $151000.0, down 42.37%, while the annual FY2025 figure was $739000.0, 43.15% down from the prior year.
  • Accumulated Depreciation & Amortization for Q1 2026 was $151000.0 at Zentalis Pharmaceuticals, down from $739000.0 in the prior quarter.
  • Over five years, Accumulated Depreciation & Amortization peaked at $1.4 million in Q4 2022 and troughed at $151000.0 in Q1 2026.
  • A 5-year average of $572058.8 and a median of $348000.0 in 2022 define the central range for Accumulated Depreciation & Amortization.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: skyrocketed 179.31% in 2024 and later plummeted 51.07% in 2025.
  • Year by year, Accumulated Depreciation & Amortization stood at $1.4 million in 2022, then decreased by 0.79% to $1.4 million in 2023, then fell by 6.41% to $1.3 million in 2024, then tumbled by 43.15% to $739000.0 in 2025, then crashed by 79.57% to $151000.0 in 2026.
  • Business Quant data shows Accumulated Depreciation & Amortization for ZNTL at $151000.0 in Q1 2026, $739000.0 in Q4 2025, and $582000.0 in Q3 2025.